Clinical Intergroup
Phase I-II-Project
Multiply
Pathology Panel
News & Dates
Paul J.Bröckelmann

Dr. med., MD Paul J. Bröckelmann

Uniklinikum Köln

Innere Medizin I - Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, Internistische Intensivmedizin
 
Kerpener Straße 62
50935 Köln
 
+49 221 4784004
 

Literature

  1. Garcia-Marquez MA, …, Bröckelmann PJ* & Schlösser HA* Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma Leukemia doi: 10.1038/s41375-021-01421-z *equal contribution IF 11.5
  2. Bröckelmann PJ, et al. Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. J Clin Oncol 2021 Jan 10;39(2):107-115I IF 44.5
  3. Borchmann P, …, Bröckelmann PJ, et al. PET-guided omission of radiotherapy in earlystage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021 Feb;22(2):223-234. IF 41.3
  4. Bröckelmann PJ, et al. Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL): A Multicenter, Randomized German Hodgkin Study Group Phase 2 Trial JAMA Oncol 2020 Apr 30 IF 31.8
  5. Reinke S*, Bröckelmann PJ*, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1 Blood 2020 Dec 17;136(25):2851-2863 *equal contribution IF 22.1
  6. Bröckelmann PJ et al. Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche J Clin Oncol 2020 Nov 10;38(32):3816-3818 IF 44.5 Bröckelmann PJ, et al. Outcomes of Patients with 3rd or Higher Relapsed Classical
  7. Hodgkin Lymphoma: Results from the German Hodgkin Study Group. Ann Oncol 2019 Mar 1;30(3):490-491 IF 32.9
  8. Bröckelmann PJ, et al. Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials J Clin Oncol 2017 May 1;35(13):1444-1450 IF 44.5
  9. Bröckelmann PJ, et al. Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 2017 Jun 1;28(6):1352-1358 IF 32.9
  10. Sasse S*, Bröckelmann PJ*, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017 Jun 20;35(18):1999-2007 *equal contribution IF 44.5